von Eschenbach AC - Search Results

1

Expediting the availability of drugs for US patients with cancer.

Farrell AT, Pazdur R, von Eschenbach AC. Farrell AT, et al. Among authors: von eschenbach ac. Nat Clin Pract Urol. 2008 Dec;5(12):654-6. doi: 10.1038/ncpuro1255. Nat Clin Pract Urol. 2008. PMID: 19050708 Review. No abstract available.

2

Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer.

Zagars GK, Pollack A, von Eschenbach AC. Zagars GK, et al. Among authors: von eschenbach ac. Urology. 2001 Aug;58(2):233-9. doi: 10.1016/s0090-4295(01)01168-2. Urology. 2001. PMID: 11489709

3

Progress with a purpose: eliminating suffering and death due to cancer.

von Eschenbach AC. von Eschenbach AC. Oncology (Williston Park). 2006 Nov;20(13):1691-6. Oncology (Williston Park). 2006. PMID: 17175745 Free article. No abstract available.

4

Spermatic cord sarcoma: outcome, patterns of failure and management.

Ballo MT, Zagars GK, Pisters PW, Feig BW, Patel SR, von Eschenbach AC. Ballo MT, et al. Among authors: von eschenbach ac. J Urol. 2001 Oct;166(4):1306-10. doi: 10.1016/s0022-5347(05)65758-8. J Urol. 2001. PMID: 11547063

5

The FDA Amendments Act: reauthorization of the FDA.

von Eschenbach AC. von Eschenbach AC. Food Drug Law J. 2008;63(2):579-84. Food Drug Law J. 2008. PMID: 18561478 No abstract available.

6

Serum testosterone--a significant determinant of metastatic relapse for irradiated localized prostate cancer.

Zagars GK, Pollack A, von Eschenbach AC. Zagars GK, et al. Among authors: von eschenbach ac. Urology. 1997 Mar;49(3):327-34. doi: 10.1016/S0090-4295(96)00619-X. Urology. 1997. PMID: 9123693

7

Relationship of ultrasound staging and bilateral biopsy positivity to outcome in stage T1c prostate cancer treated with radiotherapy.

Liebross RH, Pollack A, Lankford SP, von Eschenbach AC, Zagars GK. Liebross RH, et al. Among authors: von eschenbach ac. Urology. 1998 Oct;52(4):647-52. doi: 10.1016/s0090-4295(98)00273-8. Urology. 1998. PMID: 9763087

8

p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential.

Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, von Eschenbach AC, Logothetis CJ. Navone NM, et al. Among authors: von eschenbach ac. J Urol. 1999 Jan;161(1):304-8. J Urol. 1999. PMID: 10037428

9

State of the FDA.

von Eschenbach AC. von Eschenbach AC. Food Drug Law J. 2007;62(2):423-7. Food Drug Law J. 2007. PMID: 17632970 No abstract available.

10

Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy.

Cowen D, Troncoso P, Khoo VS, Zagars GK, von Eschenbach AC, Meistrich ML, Pollack A. Cowen D, et al. Among authors: von eschenbach ac. Clin Cancer Res. 2002 May;8(5):1148-54. Clin Cancer Res. 2002. PMID: 12006531

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

192 results

Search Page

Filters